Janssen v. Tolmar: Paliperidone Palmitate ANDA Patent Win in Landmark Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Janssen Pharmaceuticals, Inc. v. Tolmar, Inc. |
| Case Number | 1:21-cv-01784 (Del. Dist. Ct.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Dec 2021 – Mar 2024 2 years 3 months |
| Outcome | Plaintiff Win — Injunctive Relief |
| Patent at Issue | |
| Accused Products | Tolmar’s ANDA No. 211995 (generic Invega Sustenna®) |
Case Overview
The Parties
⚖️ Plaintiff
Subsidiaries of Johnson & Johnson, holding a dominant position in the long-acting injectable antipsychotic market through Invega Sustenna®.
🛡️ Defendant
Specialty pharmaceutical company that filed ANDA No. 211995 seeking FDA approval to manufacture and market a generic version of Invega Sustenna®.
The Patent at Issue
This landmark case involved U.S. Patent No. 9,439,906, covering formulation and method claims for paliperidone palmitate extended-release injectable suspension. The patent’s 21 claims protect specific pharmaceutical compositions and dosing regimens that underpin Invega Sustenna®’s clinical profile, with the ‘906 patent currently set to expire on **January 26, 2031**.
- • US 9,439,906 — Formulation and method claims for paliperidone palmitate injectable suspension
Developing a generic drug?
Check if your formulation might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Delaware District Court entered Final Judgment in favor of Janssen on March 13, 2024. The court’s ruling included the following dispositive findings: all 21 claims of U.S. Patent No. 9,439,906 are not invalid, and Tolmar’s filing of ANDA No. 211995 infringes claims 1–7, 15, and 17–21 (as dependent from claims 1 and 4). Injunctive relief was granted, barring Tolmar and its affiliates from commercializing ANDA No. 211995 products until patent expiration, effectively delaying FDA approval to no earlier than **January 26, 2031**.
Key Legal Issues
A noteworthy procedural development was the **joint stipulation on non-infringement** of claims 8–14, 16, and 17–21 (as dependent from claims 8 and 11). This selective concession by Janssen concentrated the litigation on claims 1–7 and 15, where infringement was ultimately established. The court’s upholding of all 21 claims as **not invalid** is significant, demonstrating a comprehensive validation of Janssen’s patent prosecution strategy. Furthermore, the injunction under 35 U.S.C. § 271(e)(4)(B) extending to Tolmar’s corporate affiliates showcases a critical enforcement mechanism for patent holders in multi-entity ANDA litigation.
Freedom to Operate (FTO) Analysis & Strategic Insights
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this therapeutic space
- See which companies are most active in long-acting injectables
- Understand claim construction patterns for pharma formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic formulation.
- Input your drug description or technical features
- AI identifies potentially blocking patents (e.g., US9439906)
- Get actionable risk assessment report
High Risk Area
Paliperidone palmitate injectable formulations
1 Patent Blocked
US 9,439,906 (Invega Sustenna®)
Blocked Until 2031
Generic entry delayed until patent expiry
✅ Key Takeaways
Delaware District Court upheld all 21 claims of U.S. Patent No. 9,439,906 as valid and infringed (claims 1–7, 15).
Search related case law →Bench trial format and partial stipulation strategy shaped both the scope and outcome of this ANDA dispute.
Explore precedents →Affiliate-binding injunctions under § 271(e)(4)(B) are enforceable through pre-trial dismissal stipulations — a model worth replicating.
Review injunction details →Frequently Asked Questions
The case centered on U.S. Patent No. 9,439,906, covering paliperidone palmitate extended-release injectable suspensions marketed as Invega Sustenna®.
Following a four-day bench trial, the court found all 21 patent claims valid and that Tolmar’s ANDA No. 211995 filing infringed claims 1–7, 15, and 17–21 (dependent from claims 1 and 4).
FDA approval of Tolmar’s ANDA No. 211995 cannot take effect before January 26, 2031, the ‘906 patent’s expiration date, per 35 U.S.C. § 271(e)(4)(A).
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 1:21-cv-01784
- U.S. Patent No. 9,439,906 on Google Patents
- Cornell Legal Information Institute — 35 U.S.C. § 271
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.